The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension
The DOI matches its Crossref record.
Abstract
OBJECTIVES: This study evaluated the potential effect of exenatide on the pharmacokinetics and pharmacodynamics of lisinopril in patients with mild-to-moderate hypertension. METHODS: 22 patients with mild-to-moderate primary hypertension participated in a double-blind, randomized, placebo-controlled, 2-period, 2-sequence crossover study. Patients on stable lisinopril therapy were randomly assigned to receive subcutaneous exenatide (10 microg b.i.d.) and placebo b.i.d. separated by at least 2 days washout period. The primary pharmacodynamic parameters were baseline-adjusted 24-hour mean systolic and diastolic blood pressure. Steady state plasma lisinopril concentration-time profiles were also assessed. RESULTS: Mean blood pressure changes were not significantly different between exenatide and placebo coadministered with lisinopril. The least squares mean differences (95% CI) between treatments were +1.38 mmHg (-1.41, 4.17) for diastolic and +1.38 mmHg (-1.95, 4.71) for systolic blood pressure. Exenatide delayed the time to attain maximum lisinopril concentration (tmax,ss) by 2 hours but did not significantly alter maximum lisinopril concentration (Cmax,ss) or area under the concentration-time profile (AUCtau,ss) over the 24-hour steady-state dosing interval. CONCLUSIONS: This study demonstrated that concurrent administration of exenatide did not produce clinically relevant changes in blood pressure and did not significantly alter lisinopril pharmacokinetics in patients with mild-to-moderate hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PK data on ACEI and GLP1 agonist co-treatment showed different effects by different GLP1RAs (Table 3); Still, all changes were interpreted as minor and non-clinically significant [23, 24, 30, 32, 38].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [23]
In the citing paper
“Moreover, the pharmacodynamic response was assessed by a 24-h ambulatory mean blood pressure and was unaffected [23].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [23]
Citations
Cites
Still being checked.
Cited by
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Gill, A., Hoogwerf, B. J., Burger, J., Bruce, S., MacConell, L., Yan, P., Braun, D., Giaconia, J., & Malone, J. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-6 · Cited by 133
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
“[111] Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M.”
Background
Metadata
- Authors
- Linnebjerg, H., Kothare, P., Park, S., Mace, K., & Mitchell, M.
- Affiliations
- Eli Lilly (United States) (US)
- ORCID
- Linnebjerg, H.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2009-11-01
- Volume
- 47
- Issue
- 11
- Pages
- 651-658
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2062027317
- Cited by
- 17
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2020: 2 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 3
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Clinical Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- exenatide, lisinopril, hypertension, pharmacokinetics, pharmacodynamics, blood pressure, ACE inhibitors, drug-drug interactions, GLP-1 receptor agonists, antihypertensive therapy
- MeSH terms
- Exenatide, Aged, Antihypertensive Agents, Blood Pressure, Double-Blind Method, Drug Interactions, Female, Humans, Hypertension, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Peptides, Venoms, Least-Squares Analysis, Lisinopril, Cross-Over Studies, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.